Cure8 research brief
Patients and clinicians choosing between risankizumab and upadacitinib for Crohn's disease may consider that, in this large real-world cohort, risankizumab showed greater treatment persistence overall—particularly for ileal disease—though this does not prove superiority for clinical efficacy.
Adults and children with Crohn's disease (especially those with ileal involvement), patients on or considering biologics/JAK inhibitors, gastroenterologists, and researchers studying treatment selection or real-world outcomes.
This retrospective cohort from the CREdIT registry analyzed 560 treatment episodes (264 risankizumab, 296 upadacitinib) using propensity-score weighting and multiple imputation to balance groups. The primary outcome was treatment persistence (time to drug discontinuation).
After adjustment, upadacitinib had a higher risk of discontinuation than risankizumab (HR 1.86). The difference was significant for patients with ileal involvement (HR 2.56) but not for isolated colonic disease (HR 0.66).
The authors report a significant interaction between treatment and disease location, suggesting location may influence relative persistence. This is an observational, real-world registry analysis reflecting predominantly advanced-line therapy; it reports associations with persistence rather than causal effects or efficacy outcomes.
This is a retrospective registry study of mostly treatment-experienced patients and measures persistence (time to discontinuation), not randomized efficacy. Confounding despite propensity weighting is possible. Full paper is an abstract-level source in PubMed; findings should be interpreted as observational and hypothesis-generating.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
New trial and real-world data about Skyrizi and Rinvoq could affect treatment options and conversations about long-term outcomes for people with Crohn’s disease or ulcerative colitis. Investors’ coverage can increase...
New long‑term and real‑world data for risankizumab and upadacitinib were presented at ACG 2026, which may influence treatment considerations for people with difficult‑to‑treat Crohn's disease and ulcerative colitis.
New Phase 3 and long‑term analyses presented at ACG 2026 report that risankizumab and upadacitinib showed disease control in patients with moderate‑to‑severe IBD, including difficult‑to‑treat Crohn’s disease. These...
